- Home
- ARWR vs ELAN Comparison
ARWR vs ELAN Comparison
Compare ARWR & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | ELAN |
|---|---|---|
| Founded | 2003 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.8B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARWR | ELAN |
|---|---|---|
| Price | $73.08 | $24.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $83.40 | $27.89 |
| AVG Volume (30 Days) | 1.4M | ★ 6.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | $16,142,321.00 | ★ $4,715,000,000.00 |
| Revenue This Year | N/A | $8.21 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | ★ N/A | $215.32 |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $14.30 | $13.16 |
| 52 Week High | $82.26 | $27.72 |
Technical Indicators
Market Signals| Indicator | ARWR | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 58.58 |
| Support Level | $70.19 | $23.72 |
| Resistance Level | $77.39 | $25.78 |
| Average True Range (ATR) | 3.54 | 1.12 |
| MACD | -0.75 | 0.22 |
| Stochastic Oscillator | 34.34 | 70.54 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.